| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
STVN Stock Overview
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare.
Stevanato Group Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.13 |
| 52 Week High | US$29.18 |
| 52 Week Low | US$13.36 |
| Beta | 0 |
| 1 Month Change | -7.18% |
| 3 Month Change | -19.48% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.08% |
Recent News & Updates
Shareholder Returns
| STVN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -3.5% | 2.0% | 0.3% |
| 1Y | n/a | -18.0% | -18.4% |
Return vs Industry: Insufficient data to determine how STVN performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how STVN performed against the US Market.
Price Volatility
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 7.6% |
| Life Sciences Industry Average Movement | 11.5% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: STVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: STVN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 4,652 | Franco Moro | https://www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy.
Stevanato Group Fundamentals Summary
| STVN fundamental statistics | |
|---|---|
| Market Cap | €3.91b |
| Earnings (TTM) | €125.49m |
| Revenue (TTM) | €863.15m |
31.2x
P/E Ratio4.5x
P/S RatioIs STVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STVN income statement (TTM) | |
|---|---|
| Revenue | €863.15m |
| Cost of Revenue | €595.40m |
| Gross Profit | €267.75m |
| Other Expenses | €142.25m |
| Earnings | €125.49m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 31.02% |
| Net Profit Margin | 14.54% |
| Debt/Equity Ratio | 25.8% |
How did STVN perform over the long term?
See historical performance and comparisonValuation
Is STVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STVN?
Other financial metrics that can be useful for relative valuation.
| What is STVN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €3.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.3x |
| Enterprise Value/EBITDA | 18.4x |
| PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does STVN's PE Ratio compare to its peers?
| STVN PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.9x | ||
MEDP Medpace Holdings | 25.2x | 13.4% | US$5.0b |
ABCL AbCellera Biologics | 14.4x | -52.7% | US$3.0b |
SHC Sotera Health | 41.1x | 25.9% | US$5.5b |
SYNH Syneos Health | 31x | 19.8% | US$7.5b |
STVN Stevanato Group | 31.2x | 11.0% | US$4.0b |
Price-To-Earnings vs Peers: STVN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (27.9x).
Price to Earnings Ratio vs Industry
How does STVN's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: STVN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the US Life Sciences industry average (30.3x)
Price to Earnings Ratio vs Fair Ratio
What is STVN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.2x |
| Fair PE Ratio | 24x |
Price-To-Earnings vs Fair Ratio: STVN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (24x).
Share Price vs Fair Value
What is the Fair Price of STVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: STVN ($15.13) is trading below our estimate of fair value ($33.58)
Significantly Below Fair Value: STVN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: STVN is poor value based on its PEG Ratio (2.8x)
Discover undervalued companies
Future Growth
How is Stevanato Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
11.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STVN's forecast earnings growth (11% per year) is above the savings rate (1.9%).
Earnings vs Market: STVN's earnings (11% per year) are forecast to grow slower than the US market (12.8% per year).
High Growth Earnings: STVN's earnings are forecast to grow, but not significantly.
Revenue vs Market: STVN's revenue (8.7% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: STVN's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STVN's Return on Equity is forecast to be low in 3 years time (14.6%).
Discover growth companies
Past Performance
How has Stevanato Group performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
16.5%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: STVN has a high level of non-cash earnings.
Growing Profit Margin: STVN's current net profit margins (14.5%) are lower than last year (15%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if STVN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare STVN's past year earnings growth to its 5-year average.
Earnings vs Industry: STVN earnings growth over the past year (16.5%) underperformed the Life Sciences industry 21%.
Return on Equity
High ROE: STVN's Return on Equity (14.2%) is considered low.
Discover strong past performing companies
Financial Health
How is Stevanato Group's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: STVN's short term assets (€866.4M) exceed its short term liabilities (€348.8M).
Long Term Liabilities: STVN's short term assets (€866.4M) exceed its long term liabilities (€234.1M).
Debt to Equity History and Analysis
Debt Level: STVN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if STVN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: STVN's debt is well covered by operating cash flow (58.1%).
Interest Coverage: STVN's interest payments on its debt are well covered by EBIT (40.1x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Stevanato Group current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
0.29%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate STVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STVN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STVN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: STVN is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STVN has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.5yrs
Average management tenure
CEO
Franco Moro (59 yo)
3.5yrs
Tenure
Mr. Franco Moro has been Chief Executive Officer and Director of Stevanato Group S.p.A. since February 18, 2021 and as its Chief Operating Officer since 2019. He graduated in Chemical Engineering from the...
Leadership Team
Experienced Management: STVN's management team is considered experienced (3.5 years average tenure).
Board Members
Experienced Board: STVN's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: STVN only recently listed within the past 12 months.
Top Shareholders
Company Information
Stevanato Group S.p.A.'s employee growth, exchange listings and data sources
Key Information
- Name: Stevanato Group S.p.A.
- Ticker: STVN
- Exchange: NYSE
- Founded: 1949
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$4.005b
- Shares outstanding: 264.70m
- Website: https://www.stevanatogroup.com
Number of Employees
Location
- Stevanato Group S.p.A.
- Via Molinella, 17
- Piombino Dese
- Padova
- 35017
- Italy
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/05 00:00 |
| End of Day Share Price | 2022/07/05 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.